Literature DB >> 23557879

The fatty liver index is associated with increased mortality in subjects referred to coronary angiography.

E Lerchbaum1, S Pilz, T B Grammer, B O Boehm, T Stojakovic, B Obermayer-Pietsch, W März.   

Abstract

BACKGROUND AND AIMS: Fatty liver index (FLI), a surrogate parameter for nonalcoholic fatty liver disease, is an emerging risk factor for cardiovascular diseases and mortality. We aimed to evaluate whether FLI is associated with all-cause, cardiovascular, and non-cardiovascular mortality as well as fatal cancer in a cohort of subjects routinely referred to coronary angiography. METHODS AND
RESULTS: FLI was calculated using BMI (body mass index), waist circumference (WC), triglycerides (TG) and gamma-glutamyl transferase (GGT) in 3270 subjects who were referred to coronary angiography (1997-2000). The main outcome measures were Cox proportional hazard ratios (HRs) for mortality from all causes, cardiovascular causes, non-cardiovascular causes, and fatal cancer. After a median follow-up time of 7.7 years, 740 subjects (22.6%) had died. There were 437 deaths due to cardiovascular disease and 303 deaths due to non-cardiovascular disease. Age-, sex-, and BMI-adjusted HRs (with 95% confidence intervals) for all-cause, cardiovascular, and non-cardiovascular mortality in the highest compared to the lowest FLI quartile were 2.56 (1.90-3.43; p < 0.001), 2.17 (1.47-3.22; p < 0.001), and 3.49 (2.16-5.66; p < 0.001), respectively. In age-, sex-, and BMI-adjusted analyzes, we found no significant association of FLI with fatal cancer. Multivariate adjusted HRs for all-cause, cardiovascular, non-cardiovascular mortality, and fatal cancer in the highest compared to the lowest FLI quartile were 2.17 (1.58-2.99; p < 0.001), 1.64 (1.07-2.51; p = 0.023), 3.72 (2.22-6.24; p < 0.001), and 2.33 (1.01-5.41; p = 0.048) respectively.
CONCLUSION: In subjects referred to coronary angiography, high FLI levels are independently associated with increased all-cause, cardiovascular, and non-cardiovascular mortality as well as fatal cancer.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ALT; AP; AST; All-cause mortality; BMI; C-reactive protein; CRP; Cardiovascular disease; FLI; GGT; HOMA-IR; HR; Hepatic steatosis; MS; NAFLD; Non-cardiovascular mortality; Nonalcoholic fatty liver disease; OR; TG; WC; WHR; alanine aminotransferase; alkaline phosphatase; aspartate aminotransferase; body mass index; fatty liver index; gamma-glutamyl transferase; hazard ratio; homeostatic model assessment-insulin resistance; metabolic syndrome; nonalcoholic fatty liver disease; odds ratio; triglycerides; waist circumference; waist-to-hip ratio

Mesh:

Substances:

Year:  2013        PMID: 23557879     DOI: 10.1016/j.numecd.2013.02.004

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  12 in total

1.  Benefit: "therapeutic indication".

Authors:  Hardy Walle
Journal:  Dtsch Arztebl Int       Date:  2015-02-27       Impact factor: 5.594

2.  Fatty Liver Index Independently Predicts All-Cause Mortality in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis but No Substantial Liver Disease.

Authors:  Pil Gyu Park; Jung Yoon Pyo; Sung Soo Ahn; Hyun Joon Choi; Jason Jungsik Song; Yong-Beom Park; Ji Hye Huh; Sang-Won Lee
Journal:  Front Cardiovasc Med       Date:  2022-06-23

Review 3.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

4.  Fatty liver disease: Disparate predictive ability for cardiometabolic risk and all-cause mortality.

Authors:  Altan Onat; Günay Can; Ayşem Kaya; Tuğba Akbaş; Fatma Özpamuk-Karadeniz; Barış Şimşek; Hakan Çakır; Hüsniye Yüksel
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

5.  Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease.

Authors:  Yuan-Lung Cheng; Yuan-Jen Wang; Keng-Hsin Lan; Teh-Ia Huo; Yi-Hsiang Huang; Chien-Wei Su; Wei-Yao Hsieh; Ming-Chih Hou; Han-Chieh Lin; Fa-Yauh Lee; Jaw-Ching Wu; Shou-Dong Lee
Journal:  Gastroenterol Res Pract       Date:  2017-01-17       Impact factor: 2.260

Review 6.  Non-Alcoholic Fatty Liver Disease Association with Cardiac Arrhythmias.

Authors:  Muhammad A Mangi; Hiba Rehman; Abdul M Minhas; Muhammad Rafique; Vikas Bansal; Jonathan Constantin
Journal:  Cureus       Date:  2017-04-13

7.  Association of fatty liver disease with mortality outcomes in an Eastern Finland male cohort.

Authors:  Olubunmi O Olubamwo; Jyrki K Virtanen; Jussi Pihlajamäki; Tomi-Pekka Tuomainen
Journal:  BMJ Open Gastroenterol       Date:  2019-05-24

8.  Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study.

Authors:  Jun Hyung Kim; Jin Sil Moon; Seok Joon Byun; Jun Hyeok Lee; Dae Ryong Kang; Ki Chul Sung; Jang Young Kim; Ji Hye Huh
Journal:  Cardiovasc Diabetol       Date:  2020-05-02       Impact factor: 9.951

9.  Prevalence and predictors of non-alcoholic fatty liver disease as defined by the fatty liver index in a type 2 diabetes population.

Authors:  Cristina Alina Silaghi; Horatiu Silaghi; Horatiu Alexandru Colosi; Anca Elena Craciun; Anca Farcas; Daniel Tudor Cosma; Nicolae Hancu; Raluca Pais; Carmen Emanuela Georgescu
Journal:  Clujul Med       Date:  2016-01-15

10.  Roux-en-Y Gastric Bypass Improved Insulin Resistance via Alteration of the Human Gut Microbiome and Alleviation of Endotoxemia.

Authors:  Qiping Shi; Qian Wang; Hui Zhong; Dehai Li; Shuxing Yu; Hengwen Yang; Cunchuan Wang; Zhinan Yin
Journal:  Biomed Res Int       Date:  2021-07-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.